AXT Inc vs Moderna, Inc. — how do they compare? AXT Inc trades at $80.18 (market cap $4.83B), while Moderna, Inc. trades at $60.33 (market cap $24.18B). The key difference: Moderna, Inc. is far larger — about 5× AXT Inc's market cap. Which is the better fit depends on your goals.
| AXTI | MRNA | |
|---|---|---|
Market Cap | $4.83B | $24.18B |
Sector | Technology | Health |
52-Week High | $140.83 | $81.80 |
52-Week Low | $2.05 | $22.36 |
Enterprise Value | $4.50B | $20.33B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Moderna (MRNA) trades at $59.81, up 1.08% today, with a bullish technical signal from moving averages and recent FDA approval for its mRNA flu vaccine mFLUSIVA. Despite beating Q2 2026 EPS estimates, revenue has declined from pandemic peaks, with a net income margin of -142.58% in 2026. The stock faces resistance near $61-$63, while support lies at $56-$59.
Outlook remains mixed; pipeline advancements in flu, Ebola, and oncology offer growth potential, but persistent losses and high valuation ratios pose risks. Analyst consensus is cautious with a $54.33 price target below current levels, reflecting concerns over profitability amid transitioning business focus.
Trailing returns across standard periods
Latest headlines on both assets
AXT develops and manufactures high-performance compound semiconductor wafer substrates. Its products, like indium phosphide and gallium arsenide, are essential for data centers, 5G, and consumer electronics.
Read more on AXTI →Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →